国盛证券研报指出，恒瑞医药GSK重磅BD金额超预期，“海外大药”再添重磅。恒瑞将HRS-9821（PDE3/4）项目海外权益和至多11个项目的海外权益的独家选择权有偿许可给GSK。GSK将向恒瑞支付5亿美元的首付款，如果所有项目均获得行使选择权且所有里程碑均已实现，恒瑞将有资格获得里程碑付款的潜在总金额约120亿美元，以及相应的分梯度的销售提成。HRS-9821是一款PDE3/4抑制剂，目前正处于临床开发阶段，是治疗慢性阻塞性肺病（COPD）的高潜力靶点。除HRS-9821外，其他11个项目涉及肿瘤、呼吸、自免和炎症等多个治疗领域的创新药物，目前均处于非临床研究阶段。公司创新药品种持续放量，多项大额BD交易付款增厚业绩。上调盈利预测。长期看好公司发展，维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.